\
&
Contact us
\
&
Contact us
Published on | 2 months ago
Programmes EICInnoMatch is a EU funded project within the framework of the EIC Innovation Procurement Programma. Innomatch helps public and private buyers to find and develop tailor-made solutions together. This programme enables collaboration between buyers and innovative suppliers (only open to EIC Awardees) to address challenges and deploy tailored solutions through a structured innovation procurement process.
The buyer will not receive direct funding but the selected EIC awardee will receive up to 60.000 euro of funding and will then try with the public buyer to develop and test a pilot solution or proof-of-concept demonstration that meets their expectations. The next deadline for submission is 4 February 2026. All details can be found here and if you have any additional questions you can contact cristina.roca@iclei.org
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
